This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Melanoma	VEGF receptor 2 (KDR/Flk-1; VEGFR-2)	<p>Mouse studies suggest co-delivery of engineered T cells expressing a chimeric antigen receptor (CAR) targeting VEGFR-2 and engineered T cells expressing tumor-specific T cell receptors (TCRs) could help treat melanoma. In lymphodepleted mice with established melanoma tumors, adoptive transfer of the two T cell populations plus a protocol to stimulate the transferred cells led to complete tumor regression and long-term, tumor-free survival. Next steps include dose-escalation safety studies of the anti-VEGFR-2, CAR-expressing T cells in patients.</p> <p>SciBX 6(22); doi:10.1038/scibx.2013.545 Published online June 6, 2013</p>	Patent application filed; available for licensing	<p>Chinnasamy, D. <i>et al. Cancer Res.</i>; published online April 30, 2013; doi:10.1158/0008-5472.CAN-12-3913</p> <p>Contact: Steven A. Rosenberg, National Institutes of Health, Bethesda, Md. e-mail: sar@mail.nih.gov</p>